Abstract Library

#4330 Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,

#3413 Visceral obesity at diagnosis is associated with well-differentiated neuroendocrine neoplasia lower progression free survival

Introduction: The association of well-differentiated gastroenteropancreatic neuroendocrine neoplasia (WD GEP-NEN) with metabolic syndrome (MetS), abdominal obesity, and fasting glucose abnormalities was recently described. Although the role of the intrinsic clinical, pathological, and molecular factors on GEP-NEN prognosis has been extensively studied, the association of adverse outcomes with obesity and metabolic risk factors was not identified so far.

Conference:

Presenting Author: Santos A

Authors: Santos A, Rodrigues J, Henrique R, Cardoso M, Monteiro M,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, metabolic syndrome, visceral obesity, overall survival, progression free survival,

#2245 Metastatic VIPOMA, Co-Secreting Insulin, with Complete Response to Lanreotide Combined with Capecitabine and Temozolamide

Introduction: VIPomas are rare neuroendocrine tumors (NETs) associated with vasoactive intestinal polypeptide (VIP) hypersecretion causing watery diarrhea, hypokalaemia and achlorhydria. They originate mostly in the pancreas and 60-80% are malignant. Hormonal co-secretion is rarely reported.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Marques B

Authors: Marques B, Martins R, Ribeiro J, Couto J, Ferrão H,

Keywords: vipoma, neuroendocrine, lanreotide, capecitabine, temozolamide,